We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Citigroup, Abbott Laboratories, Intercontinental Exchange, BCE and AutoZone
Read MoreHide Full Article
For Immediate Release
Chicago, IL – June 3, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Citigroup Inc. (C - Free Report) , Abbott Laboratories (ABT - Free Report) , Intercontinental Exchange, Inc. (ICE - Free Report) , BCE, Inc. (BCE - Free Report) and AutoZone, Inc. (AZO - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Citigroup, Abbott Labs and Intercontinental Exchange
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Citigroup, Abbott Laboratories and Intercontinental Exchange. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Citigroup have modestly lagged the Zacks Banks - Major Regional industry in the last six-month period (+41.4% vs. +41.7%), but the company appears well positioned for patient long-term investors. The company has an impressive earnings surprise history, having beaten the Zacks Consensus Estimate in each of the trailing four quarters.
The Zacks analyst, in fact, believes that Citigroup’s streamlining efforts, along with strategic investments in core business, bode well. Also, net interest revenues are likely to be supported by loan growth and mix, despite the low interest rate environment.
Further, manageable debt level makes it less likely to default interest and debt repayment obligations in case of any economic downturn. Efforts to enhance shareholders' value through capital deployment activities is encouraging.
However, pending litigation issues might keep legal expenses elevated for the company. Additionally, a subdued consumer banking business might dent fee income base to some extent.
Abbott shares have underperformed the Zacks Medical - Products industry in the last six-month period (-1.6% vs. +2.7%). Following a lower-than-expected earnings and revenue performance in first quarter 2021, the company in June lowered its 2021 financial guidance on declining demand for COVID testing.
The Zacks analyst believes that the company’s disappointing performance in Pediatric Nutrition is concerning. However, year-over-year improvements were robust in the first quarter. The company registered organic sales growth across each operating segment.
In Adult Nutrition, the company reported robust global demand for Ensure and Glucerna. Diabetes Care sales were strong on solid worldwide adoption of FreeStyle Libre. Diagnostics sales were extremely strong in the first quarter driven by demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Shares of Intercontinental Exchange have gained +12.2% in the last one-year period against the Zacks Securities and Exchanges industry’s gain of +12.7%. The Zacks analyst believes that Intercontinental Exchange’s top line was driven by the compelling product and service portfolio, broad range of risk management services and strength in global data services. Continued strength in its energy franchise, improving recurring market data revenues and ongoing initiatives are likely to keep growth on track.
Moreover, strategic buyouts will help it achieve cost synergies that are in sync with its aim of generating long-term value for shareholders. It is well-poised for growth on the back of accelerated digitization. However, its expenses are likely to remain elevated in the near term. Foreign currency fluctuations and stricter regulations raise concerns. Increasing interest expenses and high leverage raise financial risk.
Other noteworthy reports we are featuring today include BCE and AutoZone.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Citigroup, Abbott Laboratories, Intercontinental Exchange, BCE and AutoZone
For Immediate Release
Chicago, IL – June 3, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Citigroup Inc. (C - Free Report) , Abbott Laboratories (ABT - Free Report) , Intercontinental Exchange, Inc. (ICE - Free Report) , BCE, Inc. (BCE - Free Report) and AutoZone, Inc. (AZO - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Citigroup, Abbott Labs and Intercontinental Exchange
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Citigroup, Abbott Laboratories and Intercontinental Exchange. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Citigroup have modestly lagged the Zacks Banks - Major Regional industry in the last six-month period (+41.4% vs. +41.7%), but the company appears well positioned for patient long-term investors. The company has an impressive earnings surprise history, having beaten the Zacks Consensus Estimate in each of the trailing four quarters.
The Zacks analyst, in fact, believes that Citigroup’s streamlining efforts, along with strategic investments in core business, bode well. Also, net interest revenues are likely to be supported by loan growth and mix, despite the low interest rate environment.
Further, manageable debt level makes it less likely to default interest and debt repayment obligations in case of any economic downturn. Efforts to enhance shareholders' value through capital deployment activities is encouraging.
However, pending litigation issues might keep legal expenses elevated for the company. Additionally, a subdued consumer banking business might dent fee income base to some extent.
(You can read the full research report on Citigroup here >>>)
Abbott shares have underperformed the Zacks Medical - Products industry in the last six-month period (-1.6% vs. +2.7%). Following a lower-than-expected earnings and revenue performance in first quarter 2021, the company in June lowered its 2021 financial guidance on declining demand for COVID testing.
The Zacks analyst believes that the company’s disappointing performance in Pediatric Nutrition is concerning. However, year-over-year improvements were robust in the first quarter. The company registered organic sales growth across each operating segment.
In Adult Nutrition, the company reported robust global demand for Ensure and Glucerna. Diabetes Care sales were strong on solid worldwide adoption of FreeStyle Libre. Diagnostics sales were extremely strong in the first quarter driven by demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
(You can read the full research report on Abbott here >>>)
Shares of Intercontinental Exchange have gained +12.2% in the last one-year period against the Zacks Securities and Exchanges industry’s gain of +12.7%. The Zacks analyst believes that Intercontinental Exchange’s top line was driven by the compelling product and service portfolio, broad range of risk management services and strength in global data services. Continued strength in its energy franchise, improving recurring market data revenues and ongoing initiatives are likely to keep growth on track.
Moreover, strategic buyouts will help it achieve cost synergies that are in sync with its aim of generating long-term value for shareholders. It is well-poised for growth on the back of accelerated digitization. However, its expenses are likely to remain elevated in the near term. Foreign currency fluctuations and stricter regulations raise concerns. Increasing interest expenses and high leverage raise financial risk.
(You can read the full research report on Intercontinental Exchange here >>>)
Other noteworthy reports we are featuring today include BCE and AutoZone.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.